A new UCSF study researchers of more than 23 million people concludes that some commonly used and abused drugs pose previously unidentified risks for the development of atrial fibrillation (AF), a potentially deadly heart-rhythm disorder.
Scientists have designed compounds that hit the same key receptor that LSD activates without causing hallucinations. A single dose produced powerful antidepressant and antianxiety effects in mice that lasted up to two weeks.
Pregnant women in the U.S. are being exposed to chemicals like melamine, cyanuric acid, and aromatic amines that can increase the risk of cancer and harm child development, according to a study from researchers at UCSF and Johns Hopkins Bloomberg School of Public Health.
The Opioid Industry Documents Archive (OIDA), a project of UCSF, and Johns Hopkins University, today released more than 114,000 documents related to McKinsey & Company's work as a management consulting firm for the opioid industry.
A significant proportion of bacterial sexually transmitted infections – gonorrhea, chlamydia, or syphilis – were prevented with a dose of doxycycline after unprotected sex, according to preliminary results of a clinical trial.
In a study, UCSF neurologist William Seeley, MD, and colleagues identified two key moments in the natural history of Alzheimer’s, pointing to a window of opportunity for treatment with amyloid-lowering drugs.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
A UCSF-led study found a new drug for ALS that shows to slow or temporarily stall the progression of ALS in a select group of patients, with three times as many patients' disease slowing compared to those who received a placebo.